TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05441072

Intervention type: DEVICE
Intervention: BulbiCam
Description: The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs.

Intervention type: DEVICE
Intervention: BulbiCam
Description: The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs.

Intervention type: DEVICE
Intervention: BulbiCam
Description: The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs.

Intervention type: DEVICE
Intervention: BulbiCam
Description: The multi-test device, BulbiCam (BCAM), is a combined eye tracking; pupil metric; video graphic dual device which include the following 10 tests under development and ready for validation:~1. 26 grids glaucoma screening perimetry~2. 64 grids full perimetry (NeuroField64)~3. Pupil and Relative Afferent Pupil Defect (RAPD) assessment~4. Semi-automatic ptosis (droopy eyelid) grading~5. Video-based nystagmus test~6. Dynamic acuity and contrast sensitivity test~7. Dark adaptation test~8. Smooth pursuit eye movements~9. Saccade movements~10. Eye fixation stability~BCAM is connected to the BulbiHub software where measured data is stored and presented in numbers, diagrams, and graphs.
Study: NCT05769335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eCR
Description: Eating time window from 8:00 to 16:00

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dCR
Description: Eating time window from 12:00 to 20:00

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CR
Description: Eating time window from 8:00 to 20:00
Study: NCT06041035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: Administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 administered as IV infusion on D1/D8/D15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, oral, bid, D1-D7,D15-D21, up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m2, intravenous infusion, D1/D15, up to 6 cycles.
Study: NCT04885062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belun Ring
Description: The Belun Ring sensor will be applied to the proximal phalanx of the index finger in the non-dominant hand of the participating individuals prior to their sleep onset in the sleep lab and will be removed upon awakening at the end of the sleep period on the following morning. The attended in-lab sleep study will be performed simultaneously in a standard fashion.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSG
Description: All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
Study: NCT06171191

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Move-ARound And Get Active
Description: The intervention consists of seven sessions for parents and preschoolers, providing strategies to encourage compliance with the 24-hour movement behavior guidelines for preschoolers of the World Health Organisation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move-ARound And Get Active
Description: The intervention consists of seven sessions for parents and preschoolers, providing strategies to encourage compliance with the 24-hour movement behavior guidelines for preschoolers of the World Health Organisation.
Study: NCT06097312

Intervention type: OTHER
Intervention: Data collection
Description: The schedule of office visits and all treatment regimens will be determined by the treating health care provider. No interventions are administered as part of this protocol (observational study).
Study: NCT06572982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 300 mg Film coated tablets
Study: NCT06266338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV q 3 weeks
Study: NCT05722288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive nutritional counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06266338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg PO daily
Study: NCT05363566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airway divice
Description: inserted airway device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airway divice
Description: inserted airway device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airway divice
Description: inserted airway device
Study: NCT06486467

Intervention type: OTHER
Group type: OTHER
Intervention: Fluid challenge (cristalloids) OR passive leg raising
Description: Patients in whom fluid administration is considered necessary, based on hypoperfusion criteria will be included in the trial.~One member of group A and one of group B will proceed independently to evaluate LVOT VTI, guided by the UltraSight AI software to obtain the best 5-chamber view. The measure of LVOT VTI will be calculated as the average of three consecutive cardiac cycles.~The order of acquisition between group A and B will be randomized. Each operator will be blinded to the values obtained by the other.~After baseline LVOT VTI measurement, a 250 mL fluid challenge of crystalloids or a passive leg raising test (non-pharmacological and reversible fluid challenge of roughly 250 mL), depending on the appreciation of the clinician will be performed. Measurements will be repeated immediately after the fluid challenge by the same operators, still blinded to each other, guided by the UltraSight AI software. The order of the 2nd acquisition will be the same as the 1st acquisition

Intervention type: OTHER
Group type: OTHER
Intervention: Fluid challenge (cristalloids) OR passive leg raising
Description: Patients in whom fluid administration is considered necessary, based on hypoperfusion criteria will be included in the trial.~One member of group A and one of group B will proceed independently to evaluate LVOT VTI, guided by the UltraSight AI software to obtain the best 5-chamber view. The measure of LVOT VTI will be calculated as the average of three consecutive cardiac cycles.~The order of acquisition between group A and B will be randomized. Each operator will be blinded to the values obtained by the other.~After baseline LVOT VTI measurement, a 250 mL fluid challenge of crystalloids or a passive leg raising test (non-pharmacological and reversible fluid challenge of roughly 250 mL), depending on the appreciation of the clinician will be performed. Measurements will be repeated immediately after the fluid challenge by the same operators, still blinded to each other, guided by the UltraSight AI software. The order of the 2nd acquisition will be the same as the 1st acquisition
Study: NCT05093036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variations in PrEP care delivery at public health services
Description: Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variations in PrEP care delivery at public health services
Description: Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variations in PrEP care delivery at public health services
Description: Variations on routine PrEP care at the Public Health Services in the Netherlands: online PrEP care and reduced frequency of monitoring
Study: NCT05722288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-Term Fasting
Description: Undergo time-restricted eating
Study: NCT06574763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48/Carboplatin
Description: RC48, 2.5mg/kg, iv, Q3W Carboplatin, AUC 5, iv, D1, Q3W
Study: NCT05943236

Intervention type: DEVICE
Intervention: Radiographic assessment of the medial-distal tibial angle
Description: A long ankle view will be generated within a standard radiographic assessment and the medial-distal tibial angle will be assessed.
Study: NCT06576154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin 1000 MG
Description: * Medication: Cefazolin~* Dosage: 1 gram~* Administration Timing: A single dose will be administered preoperatively.
Study: NCT06529445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose VC004 Capsules
Description: VC004 Capsules qd per period, for two periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Median Dose VC004 Capsules
Description: VC004 Capsules qd per period, for two periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose VC004 Capsules
Description: VC004 Capsules qd per period, for two periods
Study: NCT06576440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Participants in this arm will receive a subcutaneous injection of acyl-ghrelin as the active condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Participants in this arm will receive a subcutaneous injection of acyl-ghrelin as the active condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Participants in this arm will receive a subcutaneous injection of saline as placebo control condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Participants in this arm will receive a subcutaneous injection of saline as placebo control condition.
Study: NCT04819269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tivanisiran sodium ophthalmic solution
Description: 1 drop in the affected eye(s) once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ophthalmic solution
Description: 1 drop in the affected eye(s) once daily
Study: NCT05063838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic optimisation of anaesthetic medications
Description: Personalisation of anaesthetic plan based on pharmacogenomic results and international guidelines.
Study: NCT04814329

Intervention type: OTHER
Intervention: genetic characteristic
Description: the underlying genetic characteristics that prodicting response

Intervention type: OTHER
Intervention: genetic characteristic
Description: the underlying genetic characteristics that prodicting response

Intervention type: OTHER
Intervention: genetic characteristic
Description: the underlying genetic characteristics that prodicting response
Study: NCT05751473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC)
Description: Treatment will be given by telehealth or in person, depending on the participant preference.~Content is drawn from the Full Prolonged Exposure model and condensed so as to deliver the most efficacious components in a brief format. There will be 4-6 weekly 30-minute sessions. Treatment follows the standardized PE-PC manual and workbook. At the end of the final session, the counselor and participant will review treatment progress and either conclude treatment or refer the participant to outside mental healthcare for more intensive treatment.~Participants will complete surveys and complete homework during and following the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EAP Treatment as Usual (TAU)
Description: Treatment will be given by telehealth or in person, depending on the participant preference and current EAP practices (4-6 weeks). This will be the standard of care practice at each EAP site. Usually, this includes up to six sessions of solution focused therapy, and referrals to an established network of community providers who specialize in PTSD treatment. All PTSD care received during the study will be collected and monitored as TAU. The type of TAU used will reflect the current practice in EAPs and will not be constrained in the study design. EAP staff will monitor and record all EAP care received, including tracking no shows and cancellations. Study team members will document care received outside of the EAP (including psychiatric medications) by self-report.~Participants will complete surveys and complete homework during and following the study.
Study: NCT05798195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional western medicine treatment
Description: conventional western medicine treatment only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional western medicine treatment
Description: conventional western medicine treatment only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional western medicine treatment
Description: conventional western medicine treatment only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone oral tablet
Description: treat with Dexamethasone for 2 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine decoction
Description: treat with strengthening spleen and tonifying lung decoction for 2 weeks
Study: NCT06470854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Dexmedetomidine
Description: Nebulized Dexmedetomidine was prepared to provide 1 µg/kg and the calculated dose of DXM was diluted by 4-ml of 0.9% saline and was provided in the nebulizer to be nebulized in twice daily; i.e. every 12 hours for 72 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral greater occipital nerve block
Description: The injection solution was prepared by mixing 2-ml of 2% lidocaine with 2-ml (8 mg) of dexamethasone. A line was drawn extending between the mastoid process and the external occipital protuberance, this line was divided as a medial third and lateral two-thirds to localize the occipital artery and the greater occipital nerve was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline and injection was performed bilaterally to achieve bilateral block.
Study: NCT05252767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Engagement Tools
Description: Experimental participants will receive the patient engagement tools or the educational guide after randomization. The participants in the experimental cohort will utilize the tools between visits with their clinic providers. During visits, clinic providers will review the completed tools with participants.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Educational Guide
Description: Control participants will receive a brief educational guide about pain management.
Study: NCT06063135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise Intervention
Description: Two strength training session per week and one endurance training session per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise Intervention
Description: Two strength training session per week and one endurance training session per week
Study: NCT05232825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab IV
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab SC
Description: SC Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone IV
Description: Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine IV
Description: Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone given orally
Description: Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine given orally
Description: Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
Study: NCT06325722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate Diet
Description: Consisting of 15 percent protein, 75 percent fat, and 10 percent carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate Diet
Description: Consisting of 15 percent protein, 75 percent fat, and 10 percent carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat Diet
Description: Consisting of 15 percent protein, 10 percent fat, and 75 percent carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat Diet
Description: Consisting of 15 percent protein, 10 percent fat, and 75 percent carbohydrate
Study: NCT05297500

Intervention type: DEVICE
Intervention: Pulse oximeter
Description: OLV-4202 pulse oximeter (SW version: 01-12)
Study: NCT06188806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADDUKTOR CANAL BLOCK
Description: All patients who will undergo adductor canal block are sedated with midazolam 0.03 mg/kg in the preoperative preparation room, after standard monitoring. After 2-3 ml skin infiltration with 2% lidocaine under sterile conditions, a block is applied under USG guidance.To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia )tramadol and paracetamol 10 mg / kg iv (8 hours apart) will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADDUKTOR CANAL BLOCK
Description: All patients who will undergo adductor canal block are sedated with midazolam 0.03 mg/kg in the preoperative preparation room, after standard monitoring. After 2-3 ml skin infiltration with 2% lidocaine under sterile conditions, a block is applied under USG guidance.To verify block success, sensory function is assessed by pinprick testing along the saphenous nerve distribution by comparing the pinprick sensation to the unaffected limb.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia )tramadol and paracetamol 10 mg / kg iv (8 hours apart) will be given.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CONTROL GROUP
Description: No nerve block procedure is applied to patients.All patients are monitored in the operating room and in a sitting position, 10-20 mg (2-4 ml) of heavy marcaine (0.5% bupivacaine hydrochloride and dextrose monohydrate) is applied to the subarachnoid space by entering the L3-4 or L4-5 space with a 25-gauge Whitrace needle.For postoperative multimodal analgesia, which is routinely applied to all patients, intravenous PCA (patient controlled analgesia) tramadol 50 mg at 10 mg / hour basal rate after loading (20 mg bolus dose + 30 minutes lock time) and paracetamol 10 mg / kg iv (8 hours apart) will be given.